HOME >> BIOLOGY >> NEWS
Yale licenses potential anti-HIV agent to Oncolys BioPharma of Japan

New Haven, Conn. - Yale University today announced that it has concluded a license agreement granting Oncolys BioPharma, Inc. of Tokyo the global exclusive right for clinical and business development of a novel compound for the treatment of HIV.

A patent application has been submitted by Yale for 2',3'-Didehydro-3'-Deoxy-4'-Ethynylthymidine, or Ed4T, a compound with a new and potentially effective anti-HIV clinical treatment.

Ed4T is a thymidine analogue that blocks HIV-1 reverse transcriptase, the enzyme that is essential for viral replication. The compound was discovered and developed jointly by Professor Masanori Baba of Kagoshima University and Professor Hiromichi Tanaka of Showa University in Japan, and Yung-Chi Cheng, the Henry Bronson Professor of Pharmacology at Yale University School of Medicine.

"This license agreement was possible because Yale has shown keen appreciation of our corporate philosophy -- pharmaceutical development creating timely remedies for maximum patient relief," said Yasuo Urata, President and CEO of Oncolys BioPharma. "We will give this project our concentrated effort so that patients worldwide can have the benefit of 'Ed4T'as soon as possible." Pre-clinical studies have already begun and Oncolys BioPharma will accelerate the studies with a target of initiating Phase I/II clinical trials in 2008.

An estimated 20 million people worldwide have died from AIDS and 40.3 million are infected with the virus. In 2004, a reported 1,000 patients in Japan were infected -- and the numbers are rapidly increasing.

"Yale is very proud of the contribution it makes to fighting the HIV pandemic though discovery of novel antiviral drugs," stated E. Jonathan Soderstrom, Managing Director of the Yale Office of Cooperative Research, which is responsible for licensing technologies on behalf of Ya
'"/>

Contact: Janet Rettig Emanuel
janet.emanuel@yale.edu
203-432-2157
Yale University
27-Jun-2006


Page: 1 2 3

Related biology news :

1. University of Colorado licenses two influenza virus detection discoveries to Quidel Corp.
2. Rensselaer licenses microscope technology to Thorlabs
3. Columbia University licenses next-generation DNA sequencing technology
4. Case Western Reserve University licenses methoxyamine to Tracon
5. Mount Sinai School of Medicine licenses avian flu vaccine to Avimex
6. Bayer HealthCare licenses Genomatix for microarray analysis
7. Isotron licenses ORNL cancer treatment technology
8. IC-medtech licenses promising cancer therapeutic from Summa Health System
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. Picky eating potentially perilous for bats
11. Scientists take next step in understanding potential target for ovarian cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology:
Cached News: